Worldwide Becker Muscular Dystrophy Market 2017: Latest Innovations, Drivers, DyPosted by daniel1244martinez on August 29th, 2017 Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Becker Muscular Dystrophy – Pipeline Review, H2 2017, provides an overview of the Becker Muscular Dystrophy (Genetic Disorders) pipeline landscape. Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls. Browse Full Table of Contents and Report Description @ https://www.reportsmonitor.com/becker-muscular-dystrophy-pipeline-review-h2-2017/ Report Highlights Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Becker Muscular Dystrophy – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 2 respectively. Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope – The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders). – The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. – The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. – The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects. – The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. – The pipeline guide encapsulates all the dormant and discontinued pipeline projects. – The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) Reasons to buy – Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. – Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. – Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders). – Classify potential new clients or partners in the target demographic. – Develop tactical initiatives by understanding the focus areas of leading companies. – Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. – Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics. – Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. – Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For Requesting a Sample Copy of This Report, Please Visit @ https://goo.gl/CNSKLR Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Becker Muscular Dystrophy – Overview Becker Muscular Dystrophy – Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Becker Muscular Dystrophy – Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Becker Muscular Dystrophy – Companies Involved in Therapeutics Development Italfarmaco SpA Milo Biotechnology LLC PTC Therapeutics Inc ReveraGen BioPharma Inc Sarepta Therapeutics Inc Becker Muscular Dystrophy – Drug Profiles AAV1-Follistatin – Drug Profile Product Description Mechanism Of Action R&D Progress Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD – Drug Profile Product Description Mechanism Of Action R&D Progress ARM-210 – Drug Profile Product Description Mechanism Of Action R&D Progress ataluren – Drug Profile Product Description Mechanism Of Action R&D Progress epicatechin – Drug Profile Product Description Mechanism Of Action R&D Progress givinostat – Drug Profile Product Description Mechanism Of Action R&D Progress vamorolone – Drug Profile Product Description Mechanism Of Action R&D Progress Becker Muscular Dystrophy – Dormant Projects Becker Muscular Dystrophy – Product Development Milestones Featured News & Press Releases Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference Mar 31, 2015: Cardero Therapeutics Presents at 2015 Muscular Dystrophy Association Scientific Conference Sep 30, 2014: Becker Trial completed at UC-Davis on the Cardero Therapeutics lead compound May 31, 2013: Becker Trial initiated at UC-Davis on the Cardero Therapeutics lead compound Mar 31, 2013: Completed triglyceride trial with Cardero Therapeutics lead compound Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer About Us Contact Us Like it? Share it! More by this author |